Estimation of CRP and some hematological parameters with COVID -19 patients using ANOVA as a statistical tool

Abstract

Coronaviruses (CoVs) are a group of related viruses that can cause respiratory tract infection in humans ranging from mild symptoms to lethal outcomes. Serum CRP is the major indicators of inflammatory severity in intensive care medicine, had significantly increased or stayed at a relatively high level in death event group, and is closely related to poor recovery of COVID-19 patients. (CRP), point to development of a systemic inflammatory response syndrome (SIRS) picture in patients with a severe form of the disease. Hematologic biomarkers used to stratify COVID-19 patients include WBC (leukocyte) count, lymphocyte count. WBCs may signify clinical worsening and increased risk of a poor outcome. With the SARS virus, it was suspected that lymphocytes are essential to eliminating virally infected cells.

This study was conducted on (267) patients who diagnosed with, SARS -COV2, patients were divided into three age group the first group number (68) patient’s _young age _ (18-39) years and the second number (109) patient’s _middle age_ (40-62) year’s, The third group number (98) patient’s _elderly_ (63-85) years. The Fresh blood (3 ml) sample collected from each patient for whole blood and serum, The serum CRP model was determined by using Roche Cobas Integra 400 plus (Roche diagnostics GmbH, Mannheim, Germany) that the principle of device action by four measuring technologies: Absorbance photometry, Turbidity, Fluorescence polarimetry, Ion – Selective electrode, Whole blood CBC assay done by full automated counter by Sysmex device.